Led Excellergy's $70M Series A alongside Red Tree Venture Capital and Decheng Capital, backing a new class of allergy therapeutics (ECRIs).
Excellergy is pioneering a new class of allergy therapeutics with a singular mission: to end allergic suffering by disabling the IgE axis
Excellergy is pioneering a new class of allergy therapeutics with a singular mission: to end allergic suffering by disabling the IgE axis. The company is developing Effector Cell Response Inhibitors (ECRIs) that target IgE to provide rapid and complete control of allergic responses.